BioSpace News Archive

Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced that it will release its unaudited financial results for the third quarter of 2022 before the U.S. market opens on Tuesday, November 29, 2022.

Clearside Biomedical, Inc. announced today that management will participate in the following conferences in November and December 2022.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced financial results for the three and nine months ended September 30, 2022.

Milestone Pharmaceuticals Inc. today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY.

Telix Pharmaceuticals Limited announces Illuccix® with up to 50mCi for radiolabeling is available for use on 100mCi gallium generators, an important development in radioisotope production.

Nanoscope Therapeutics Inc. today announced that management will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, in New York.

Coeptis Therapeutics Holdings, Inc. today announced an agreement with IQVIA, a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, to support the development of SNAP-CAR, a multi-antigen chimeric antigen receptor T cell (CAR T) technology that Coeptis licensed from the University of Pittsburgh.

Approval based on a Phase 3 trial that demonstrated significant survival benefit in patients with recurrent or metastatic cervical cancer, with Libtayo reducing the risk of death by 31% compared to chemotherapy during the study.

Numinus Wellness Inc. today announced that Payton Nyquvest , Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022, at 11:00 a.m. ET / 8:00 a.m. PT.

ZyVersa Therapeutics, Inc. are pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and Chairman, and Karen A. Cashmere, ZyVersa’s Chief Commercial Officer, are invited speakers at the 4th Inflammasome Therapeutics Summit.